Indefinite Delivery Contract 36C24E23D0025

Award Date 5/1/23
Last Date to Order 4/30/26
Ultimate Awardee
Irisys, Inc.
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4 awarded a single award indefinite delivery contract to Societal Cdmo San Diego, LLC to provide imiquimod for research purposes. A $796,700 firm fixed price delivery order was issued for the prime contractor to supply imiquimod from December 2021 through December 2022, with performance in Allegheny-West, Pennsylvania. Originally, the VA Cooperative Studies Program Clinical Research Pharmacy...
The Department of Veterans Affairs (VA) has awarded an Indefinite Delivery Contract (IDC) valued at $817,500.00 to Lovell Government Services Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), for the supply of Imiquimod 5% cream and matching placebo. The contract has an ultimate completion date of January 14, 2028. This IDC is a single-award contract issued by the VA's Network Contracting Office 22 to procure the medical products for a clinical research study being conducted by the...
Societal Cdmo San Diego, LLC, a small disadvantaged business and subsidiary of Irisys, Inc., was awarded an Indefinite Delivery Contract by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued up to $6 million, is for the SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL services to support the NCI's cancer research and drug development programs. Under this Indefinite Delivery Contract,...
The Department of Veterans Affairs (VA) National Acquisition Center has awarded Organon LLC a single-award Indefinite Delivery Contract (IDC) valued at $325,063,436.44 to provide Adalimumab pen and syringe kits. The contract has a base year of March 9, 2024 to March 8, 2025, with four one-year option periods, for a total potential period of performance through March 8, 2026. The IDC will support the VA's Pharmaceutical Prime Vendor program, as well as provide Adalimumab products to the Bureau of...
The National Acquisition Center, a civilian agency within the U.S. Department of Veterans Affairs (VA), awarded a single-award Indefinite Delivery Contract (IDC) to Golden State Medical Supply, Inc. to provide Imatinib Mesylate tablets. The $13,958,283 contract has a base period of one year and four one-year option periods, running from February 27, 2022 to February 26, 2026. The IDC allows the VA, Department of Defense, Bureau of Prisons, and Indian Health Service to place delivery orders...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract to Avkare, LLC, a for-profit limited liability company, to provide abiraterone tablets. This 1-year base contract with four 1-year option periods has a potential value of $70,208,375.13. The contract will supply the VA, Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS) with an uninterrupted source of abiraterone acetate 250mg tablets, with an...
The Department of Veterans Affairs National Acquisition Center awarded a single-award, indefinite delivery contract to Golden State Medical Supply, Inc. to provide calcipotriene cream and ointment. The contract has a potential value of $12,762,937.05 and a period of performance from March 31, 2022 to March 30, 2023, with four one-year option periods. The contract aims to procure calcipotriene cream and ointment in various sizes for distribution through the VA and Department of Defense...
The Department of Veterans Affairs National Acquisition Center has awarded Organon LLC a single-award Indefinite Delivery Contract (IDC) worth up to $119,538,562.32 to provide Infliximab Injection 100 mg/vial, a biosimilar medication, to the VA, Bureau of Prisons, and Indian Health Service. The contract has a 1-year base period starting September 1, 2023 with four 1-year option periods, for a total potential period of performance through August 31, 2026. This IDC supports the VA's Pharmaceutical...
The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract to Golden State Medical Supply, Inc. for the provision of Ketoconazole 2% Cream. With a potential value of $11.9 million over five years and no set-aside used, the IDV facilitates orders for the cream in 15g, 30g, and 60g tube sizes to support the VA and DoD Pharmaceutical Prime Vendor programs. The originating pre-solicitation notice sought offers for an unrestricted contract to...
This Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Golden State Medical Supply, Inc., a for-profit manufacturer and distributor of pharmaceuticals and medical products. The contract has a ceiling value of $8,612,710.75 and covers the supply of mycophenolic acid tablets in 180mg and 360mg strengths to the VA, Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). This single-award IDC has...
  • 36C24E23D0025
    Indefinite Delivery Contract
  • 1
    Federal Contract Awards

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4 awarded a single-award, indefinite delivery contract to Societal Cdmo San Diego, LLC for the delivery of pharmaceutical products. The contract has a potential value of $2,010,645 and period of performance through April 2026. Societal Cdmo San Diego, LLC was awarded an initial firm fixed price delivery order valued at $1,136,781.80 to supply placebo and active imiquimod from May 2023 through April 2024 in Allegheny-West, Pennsylvania.

This contract and associated delivery order aim to procure placebo and active imiquimod pharmaceutical products to support a VA clinical study investigating the use of imiquimod 5% cream for cancer prevention. Specifically, the delivery order requires Societal Cdmo San Diego, LLC to supply matching placebo and active imiquimod 5% cream formulations for use in a trial studying the effects of chemoprevention on the recurrence of basal cell carcinoma. The original solicitation sought a sole source provider capable of developing therapeutic equivalent imiquimod formulations for FDA Investigational New Drug application and subsequent manufacturing and supply to the VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center in Albuquerque, New Mexico.

Generated 1/5/24, 1:26 AM